et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007 (Letter)
Retrospective 115 ivermectin patients and 133 control patients showing significantly lower death and faster viral clearance.
Some potential issues and the authors' response can be found in [1, 2].
Khan et al., 9/24/2020, retrospective, Bangladesh, South Asia, preprint, median age 35.0, 8 authors, dosage 12mg single dose.
risk of death, 87.0% lower, RR 0.13, p < 0.05, treatment 1 of 115 (0.9%), control 9 of 133 (6.8%).
risk of ICU admission, 89.5% lower, RR 0.11, p = 0.007, treatment 1 of 115 (0.9%), control 11 of 133 (8.3%).
time to viral-, 73.3% lower, relative time 0.27, p < 0.001, treatment 115, control 133.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.